Home » Stocks » KNTE

Kinnate Biopharma, Inc. (KNTE)

Stock Price: $38.30 USD -1.70 (-4.25%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 1.66B
Revenue (ttm) n/a
Net Income (ttm) -26.00M
Shares Out 41.53M
EPS (ttm) -0.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $38.30
Previous Close $40.00
Change ($) -1.70
Change (%) -4.25%
Day's Open 40.05
Day's Range 38.05 - 40.00
Day's Volume 72,956
52-Week Range 36.35 - 45.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 3 weeks ago

Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multip...

Other stocks mentioned: AYTU, MYOV, OSMT
Benzinga - 3 weeks ago

Kinnate Biopharma Inc (NASDAQ: KNTE), which focuses on developing small-molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, recently raised $276 million in gross pr...

GlobeNewsWire - 1 month ago

SAN FRANCISCO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small ...

Seeking Alpha - 1 month ago

The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education & Technology Group. Two companies, Ondas and A...

Other stocks mentioned: FTCVU, LOKBU, POWW, SBTX, SEER, SGAMU, YQ
InvestorPlace - 1 month ago

KNTE stock has rocketed higher by as much as 115% following the Kinnate Biopharma IPO. Here's what you should know right now.

Market Watch - 1 month ago

Kinnate Biopharma shares more than doubled in their trading debut Thursday, after the company upsized its initial public offering and priced it above its proposed range. The stock, trading on ...

Investors Business Daily - 1 month ago

Kinnate Biopharma is a preclinical biotech focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat cancers. The IPO raised $240 million.

Market Watch - 1 month ago

Kinnate Biopharma upsized its initial public offering on Wednesday and priced it at $20 a share, above its $18 to $19 proposed price range. The company sold 12 million shares, or more than the...

GlobeNewsWire - 1 month ago

SAN FRANCISCO and SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small ...

Market Watch - 1 month ago

Kinnate Biopharma set terms for its initial public offering on Wednesday with plans to offer 11.5 million shares priced at $18 to $19 each. The company would raise $218.5 million at the top of...

TheStreet - 1 month ago

The firm is developing treatments for various cancers using a kinase inhibitory approach.

NASDAQ - 2 months ago

Kinnate Biopharma, an oncology biotech developing small molecule kinase inhibitors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

SEC - 2 months ago

Kinnate Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.

About KNTE

Kinnate Biopharma, a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. The company's lead product candidate is KIN002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. Its other products in preclinical stage include KIN003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth facto... [Read more...]

Industry
Biotechnology
IPO Date
Dec 3, 2020
CEO
Nima Farzan
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
KNTE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for KNTE stock is "Buy." The 12-month stock price forecast is 52.00, which is an increase of 35.77% from the latest price.

Price Target
$52.00
(35.77% upside)
Analyst Consensus: Buy